Description

Buy Ultima-Cagri+Sema Blend US

Ultima-Cagri+Sema Blend is a research-grade combination peptide product containing cagrilintide and semaglutide, two investigational compounds being studied for their synergistic effects on weight management and metabolic health . This blend is designed for laboratory research applications investigating the combined mechanisms of amylin and GLP-1 receptor agonism.

Cagrilintide is a long-acting analogue of the satiety hormone amylin, which delays gastric emptying and enhances feelings of fullness through central mechanisms . Semaglutide is a well-characterized glucagon-like peptide-1 (GLP-1) receptor agonist that reduces hunger and increases satiety. Together, these compounds represent a novel combination approach to studying metabolic regulation .

This combination, known in clinical research as CagriSema, is being investigated by Novo Nordisk in the REDEFINE and REIMAGINE clinical trial programs for adults with obesity, overweight, and type 2 diabetes .

Mechanism of Action

Cagrilintide, the amylin analogue, acts by:

• Delaying gastric emptying

• Enhancing central satiety signaling

• Reducing food intake

Semaglutide, the GLP-1 receptor agonist, acts by:

• Stimulating insulin secretion

• Suppressing glucagon release

• Delaying gastric emptying

• Reducing appetite through central pathways

When combined, these two compounds produce complementary effects on weight regulation. Preclinical research in rats has shown that CagriSema drives weight loss through both reduced energy intake and preservation of energy expenditure, with approximately one-third of the weight loss efficacy attributed to effects on energy expenditure .

Clinical Research Findings

Recent clinical trial data on the CagriSema combination has demonstrated significant weight loss outcomes:

REDEFINE 1 (Adults with Obesity/Overweight without Diabetes)

In a 68-week phase 3 trial involving 3,417 participants, those treated with cagrilintide-semaglutide achieved:

• Mean weight loss of 20.4% from baseline (placebo: 3.0%) 

• Weight loss of 22.7% when evaluating participants who stayed on treatment 

• 91.9% achieved ≥5% weight reduction (placebo: 31.5%) 

• 54% reached a BMI below 30 (non-obese threshold) 

REDEFINE 2 (Adults with Type 2 Diabetes and Obesity/Overweight)

In a 68-week phase 3 trial involving 1,206 participants:

• Mean weight loss of 13.7% (placebo: 3.4%) 

• Weight loss of 15.7% when evaluating adherent participants 

• 83.6% achieved ≥5% weight reduction (placebo: 30.8%) 

• 73.5% achieved HbA1c ≤6.5% (placebo: 15.9%) 

Safety Profile

Gastrointestinal adverse events were the most commonly reported, including nausea, vomiting, diarrhea, and constipation. These were mainly transient and mild-to-moderate in severity, consistent with the GLP-1 receptor agonist class . Discontinuation rates due to adverse events were low: 5.9% in REDEFINE 1 and 8.4% in REDEFINE 2 .

Product Features

• Research-Grade Quality: Manufactured to high purity standards for laboratory research

• Lyophilized Format: Stable powder for reliable storage and reconstitution

• Combination Formulation: Contains both cagrilintide and semaglutide in a single vial

• Precise Dosing: Allows for accurate research protocol implementation

Research Applications

Ultima-Cagri+Sema Blend is suitable for:

• Metabolic Research: Investigating combined GLP-1 and amylin receptor agonism on weight and glucose metabolism

• Appetite Regulation Studies: Examining central and peripheral mechanisms of satiety

• Energy Expenditure Research: Studying the effects on metabolic adaptation and energy balance 

• Glycemic Control Investigations: Research on combination therapy for diabetes management 

Recommended Use

This product is intended solely for laboratory research purposes. The lyophilized powder must be reconstituted with sterile water or bacteriostatic water before use.

Reconstitution Instructions

1. Clean the rubber stopper with an alcohol swab

2. Draw the appropriate amount of sterile water into a sterile syringe

3. Inject the water slowly against the glass wall of the vial to avoid foaming

4. Gently swirl until completely dissolved; do not shake vigorously

5. Use immediately or store as directed for research protocols

Storage Instructions

• Lyophilized Powder: Store in the refrigerator at 2–8°C

• Protect from Light: Keep in original packaging

• Do Not Freeze: Avoid freezing the product

• After Reconstitution: Use promptly or store as directed for research protocols

Top 10 Frequently Asked Questions

1. What is Ultima-Cagri+Sema Blend?
Ultima-Cagri+Sema Blend is a research-grade combination peptide product containing cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist), designed for metabolic research applications.

2. What is the mechanism of action of this combination?
Cagrilintide delays gastric emptying and enhances satiety through central pathways, while semaglutide reduces appetite and stimulates insulin secretion. Together, they produce complementary effects on weight and glucose metabolism .

3. What clinical trial results have been reported for CagriSema?
REDEFINE 1 trial: 20.4% mean weight loss in participants without diabetes (placebo: 3.0%). REDEFINE 2 trial: 13.7% mean weight loss in participants with type 2 diabetes (placebo: 3.4%) .

4. What are the most common side effects observed in clinical trials?
Gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation were most common. The vast majority were mild to moderate in severity and transient .

5. What is the dosing schedule investigated in clinical research?
The once-weekly subcutaneous dose of 2.4 mg cagrilintide and 2.4 mg semaglutide has been studied in phase 3 clinical trials .

6. How does this combination compare to semaglutide alone?
In REDEFINE 1, CagriSema achieved 20.4% weight loss compared to 14.9% with semaglutide alone, demonstrating superior efficacy .

7. Is CagriSema approved for clinical use?
CagriSema is not approved in the US or EU. Novo Nordisk submitted a New Drug Application to the FDA in December 2025, with review expected in 2026 .

8. What research applications is this product suitable for?
Metabolic research, appetite regulation studies, energy expenditure research, and glycemic control investigations .

9. How should this product be stored?
Lyophilized powder should be stored in the refrigerator at 2–8°C, protected from light, and not frozen.

10. Is this product suitable for human use?
No. This product is intended solely for laboratory research purposes and is not suitable for human or animal consumption.

---

Ready to take the next step?
Secure your supply of Ultima-Cagri+Sema Blend US from a trusted source. Visit anabolicsteroidsonline.shop today to explore our selection of premium research products.